| Baricitinib as potential treatment for 2019-nCoV acute respiratory disease P Richardson, I Griffin, C Tucker, D Smith, O Oechsle, A Phelan, ... The lancet 395 (10223), e30-e31, 2020 | 1660 | 2020 |
| COVID-19: combining antiviral and anti-inflammatory treatments J Stebbing, A Phelan, I Griffin, C Tucker, O Oechsle, D Smith, ... The Lancet Infectious Diseases 20 (4), 400-402, 2020 | 1309 | 2020 |
| Expert-augmented computational drug repurposing identified baricitinib as a treatment for COVID-19 DP Smith, O Oechsle, MJ Rawling, E Savory, A Lacoste, PJ Richardson Frontiers in Pharmacology 12, 709856, 2021 | 41 | 2021 |
| Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma DM Carvalho, PJ Richardson, N Olaciregui, R Stankunaite, C Lavarino, ... Cancer discovery 12 (2), 416-431, 2022 | 33 | 2022 |
| The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19 PJ Richardson, BWS Robinson, DP Smith, J Stebbing Vaccines 10 (6), 951, 2022 | 15 | 2022 |
| Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis PJ Richardson, DP Smith, A de Giorgio, X Snetkov, J Almond-Thynne, ... Translational Neurodegeneration 12 (1), 47, 2023 | 8 | 2023 |
Justin StebbingImperial College在 imperial.ac.uk 的电子邮件经过验证
Justin StebbingImperial College在 imperial.ac.uk 的电子邮件经过验证
Alix M.B. LacosteInvitae, Harvard University, IBM Watson Health, BenevolentAI在 invitae.com 的电子邮件经过验证